ReviewFrontiers in oncology2025
Advances in hepatic arterial perfusion chemotherapy for hepatic metastases.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Best available evidence for the management of oxaliplatin-induced hypersensitivity reactions, with implications for hepatic arterial infusion chemotherapy (HAIC).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Review
- FOLFOX-HAIC Plus Lenvatinib and Tislelizumab in Advanced Hepatocellular Carcinoma with Arteriovenous Fistulae: A Real-World Study.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatic arterial infusion chemotherapy (HAIC) is one of the local treatment modalities employed for liver metastases. HAIC targets the delivery of chemotherapy drugs to the affected area by inserting a catheter into the tumor's blood-supplying artery. This approach not only enhances drug concentration within the tumor site, but also significantly reduces systemic side effects. Currently, there are various chemotherapeutic regimens available for HAIC in liver metastases; however, determining the optimal therapeutic agent remains elusive. This article provides a comprehensive review of HAIC dosing regimens and multimodal therapy for liver metastases originating from colorectal, breast, and gastric cancers. Meanwhile, this paper briefly outlines ongoing research on HAIC treatment for liver metastases associated with esophageal cancer, gastroenteropancreatic neuroendocrine tumors, and uveal melanoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.